Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development

Claret Capital Partners has invested €43m in clinical-stage biopharmaceutical company Inventiva as part of a €130m debt financing round. Inventiva is developing lanifibranor, an oral therapy for MASH (metabolic dysfunction-associated steatohepatitis), with Phase 3 trial results expected in Q4 2026. The financing, alongside BlackRock-managed funds, aims to support the company through key clinical and regulatory milestones.

06/16/2026, 4:52 AM • GlobeNewswire

Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing

Inventiva completed repayment of €62 million in EIB loans and repurchased EIB warrants for €50 million. The company simultaneously issued €75 million in new debt financing (€35 million convertible bonds and €40 million amortized bonds) from BlackRock and Claret Capital Partners, following a successful €120 million equity offering of ADSs at $4.40 per share.

06/12/2026, 4:00 PM • GlobeNewswire

Assemblée Générale Mixte du 30 juin 2026 - Modalités de mise à disposition des documents préparatoires

Inventiva announced the arrangements for its Mixed General Assembly scheduled for June 30, 2026 in Paris. The agenda includes a 39th resolution regarding a master agreement with the European Investment Bank (EIB) signed on June 1, 2026, which involves full repayment of existing EIB loans and repurchase of warrant subscription rights (BSA) for €50 million. The company also adjusted caps for resolutions related to free share allocations and warrant issuances based on recent board decisions.

06/09/2026, 4:00 PM • GlobeNewswire

Information relative au nombre total de droits de vote et d’actions composant le capital social au 22 mai 2026

Inventiva, a clinical-stage biopharmaceutical company, announced the resumption of trading for its ordinary shares on Euronext Paris and provided information on its Combined General Meeting scheduled for June 30, 2026. As of May 22, 2026, the company had 209,007,475 shares in circulation with 218,082,368 total voting rights.

06/09/2026, 4:00 PM • GlobeNewswire

Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026

Inventiva, a clinical-stage biopharmaceutical company, announced the resumption of trading for its ordinary shares on Euronext Paris and disclosed preparatory documents for its Combined General Meeting scheduled for June 30, 2026. The company has 209,007,475 shares outstanding with 218,082,368 total voting rights as of May 22, 2026.

06/09/2026, 4:00 PM • GlobeNewswire

Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents

Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH, announced the availability of preparatory documents for its Combined General Meeting scheduled for June 30, 2026. The meeting agenda includes a 39th resolution related to a master agreement with the European Investment Bank (EIB) for full repayment of existing loans and buyback of warrants for €50 million, with issuance of new warrants on standard terms. The company is currently evaluating lanifibranor in the NATiV3 Phase 3 clinical trial.

06/09/2026, 4:00 PM • GlobeNewswire

Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris

Inventiva announced on June 2, 2026, that trading of its ordinary shares on Euronext Paris will be temporarily suspended starting at market open (9:00 CEST) pending disclosure of a financing operation. Trading is expected to resume later that day around 15:30 CEST, coinciding with potential trading resumption on Nasdaq. The company is a clinical-stage biopharmaceutical firm developing lanifibranor, a pan-PPAR agonist, for treating MASH (metabolic dysfunction-associated steatohepatitis).

06/02/2026, 1:30 AM • GlobeNewswire

Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH treatment, announced a temporary trading halt on Euronext Paris on June 2, 2026, ahead of a proposed financing transaction. Trading was expected to resume at approximately 3:30 p.m. CEST, coinciding with the opening of Nasdaq trading. The company reported Q1 2026 cash and equivalents of €75.0 million plus €121.5 million in short-term deposits.

06/02/2026, 1:30 AM • GlobeNewswire

Inventiva Reports 2026 First Quarter Financial Information¹

Inventiva, a clinical-stage biopharmaceutical company, reported Q1 2026 financial results showing cash and cash equivalents of €75.0 million and short-term deposits of €121.5 million, down from €99.3 million and €131.6 million respectively at year-end 2025. The company estimates its current resources will fund operations until mid-Q1 2027, or mid-Q3 2027 if Tranche 3 warrants from its October 2024 structured financing are fully exercised for €116.0 million. The company generated no revenues in Q1 2026 and expects NATiV3 Phase 3 trial topline results in Q4 2026.

05/26/2026, 4:00 PM • GlobeNewswire

Inventiva publie ses informations financières du premier trimestre 2026¹

Inventiva, a clinical-stage biopharmaceutical company, reported cash and equivalents of €75 million and short-term deposits of €121.5 million as of March 31, 2026. The company estimates its liquidity will fund operations until mid-Q1 2027, or potentially mid-Q3 2027 if warrant exercises from its structured financing reach €116 million. No revenue was recorded in Q1 2026. Key milestone: NATiV3 Phase 3 trial results for lanifibranor (MASH treatment) are expected in Q4 2026.

05/26/2026, 4:00 PM • GlobeNewswire

Inventiva to Present at 2026 Jefferies Global Healthcare Conference

Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH treatment, announced that CEO Andrew Obenshain will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, in New York City. The company is evaluating lanifibranor, a pan-PPAR agonist, in the NATiV3 Phase 3 clinical trial.

05/21/2026, 4:00 PM • GlobeNewswire

Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference

Inventiva announced that CEO Andrew Obenshain will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026 in New York. The biopharmaceutical company is developing lanifibranor, an oral therapy for MASH treatment, currently in Phase 3 clinical trials.

05/21/2026, 4:00 PM • GlobeNewswire

Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026

Inventiva announced it will present two abstracts at the EASL Congress 2026 in Barcelona (May 27-30) showcasing lanifibranor's improvements in histological parameters and cardiometabolic markers in MASH patients, independent of weight change and associated with adiponectin induction. The company will also exhibit at booth 35.

05/13/2026, 2:30 AM • GlobeNewswire

Inventiva to Present Abstracts at the EASL Congress 2026

Inventiva announced it will present two abstracts at the EASL Congress 2026 in Barcelona (May 27-30) showcasing lanifibranor's effectiveness in treating metabolic dysfunction-associated steatohepatitis (MASH). The presentations highlight improvements in histological parameters, cardiometabolic markers, and liver sinusoidal endothelial cell changes independent of weight loss. Lanifibranor is a pan-PPAR agonist currently in Phase 3 clinical trials and has received FDA Breakthrough Therapy and Fast Track designations.

05/13/2026, 2:30 AM • GlobeNewswire

Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor

Inventiva announced the recruitment of three new senior executives: Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These appointments strengthen the company's leadership team ahead of the anticipated Phase 3 top-line data readout for lanifibranor in Q4 2026. Previous CFO Jean Volatier will transition to EVP Finance & Corporate Social Responsibility.

04/22/2026, 4:00 PM • GlobeNewswire